# A Study of SGN-STNV in Advanced Solid Tumors

> **NCT04665921** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 111 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung
- HER2 Negative Breast Neoplasms
- Ovarian Neoplasms
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Gastroesophageal Junction Carcinoma
- Stomach Neoplasms
- Colorectal Neoplasms
- Exocrine Pancreatic Adenocarcinoma
- Appendiceal Adenocarcinoma
- Pseudomyxoma Peritonei

## Interventions

- **DRUG:** SGN-STNV

## Key facts

- **NCT ID:** NCT04665921
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-18
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665921, "A Study of SGN-STNV in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04665921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*